Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05997615

Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Hormone-refractory Prostate Cancer Clinical Trial

Official title:
A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical Trial Summary

The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2). - Part 1 (Monotherapy Dose Escalation): Single-agent AMX-500 dose escalation - Part 2 (Monotherapy Dose Expansion): Single-agent AMX-500 dose expansion The study may subsequently continue via a protocol amendment with dose escalation of AMX-500 combinations (Part 3) followed by combination therapy dose expansion (Part 4).

Clinical Trial Description

Duration of the study up to approximately 48 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05997615
Study type Interventional
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email contact-us@sanofi.com
Status Recruiting
Phase Phase 1/Phase 2
Start date August 10, 2023
Completion date September 29, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT03076203 - Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) Phase 1
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Completed NCT00201357 - An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer Phase 2
Completed NCT00337077 - Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Phase 2
Completed NCT00675545 - A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients Phase 2
Completed NCT01133704 - Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT03016741 - Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Phase 4
Completed NCT00570700 - Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer Phase 2
Completed NCT02288936 - Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer Phase 2
Completed NCT00636740 - Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Completed NCT01422850 - Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy Phase 1
Recruiting NCT03658434 - Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer N/A
Completed NCT00891345 - Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy Phase 1
Completed NCT00151073 - Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate Phase 2
Terminated NCT00048659 - YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Phase 2
Completed NCT00082134 - Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel Phase 2